SCHEMBL3559002

SCHEMBL3559002

CC(=O)C#Cc1ccc(C#N)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 2/20 0.47
CA2 P00918 3/20 0.47
CA1 P00915 2/20 0.47
ALDH1A1 P00352 3/20 0.44
CYP2A6 P11509 2/20 0.44
MAPT P10636 1/20 0.44
CA12 O43570 1/20 0.44
CA3 P07451 1/20 0.44
CA6 P23280 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
NOS3 P29474 2/20 0.44
NOS1 P29475 2/20 0.44
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MEN1 O00255 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41
KMT2A Q03164 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7118049 0.80 GSK3B (0.48) GSK3BCA2CA1ALDH1A1CYP2A6
SCHEMBL12430908 0.80 VCP (0.53) CA2CA1ALDH1A1CYP2A6CA12
SCHEMBL8444868 0.78 GSK3B (0.47) GSK3BCA2CA1ALDH1A1CYP2A6
SCHEMBL31182393 0.78 FFAR1 (0.50) GSK3BCA2CA1ALDH1A1CYP2A6
SCHEMBL22905187 0.78 APP (0.53) CA2CA1ALDH1A1RAB9AKDM4E
SCHEMBL28722702 0.78 ACACB (0.46) GSK3BCA2CA1ALDH1A1MAPT
SCHEMBL31182389 0.78 FFAR1 (0.50) GSK3BCA2CA1ALDH1A1CYP2A6
SCHEMBL4487823 0.78 ACACB (0.46) GSK3BALDH1A1MAPTRAB9AKDM4E
SCHEMBL9432042 0.78 GABRP (0.48) GSK3BCA2CA1ALDH1A1CYP2A6
4-Phenyl-3-Butyn-2-One SCHEMBL433104 0.77 NPSR1 (0.61) ALDH1A1MAPTRAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2468727-A1 Pyridine and pyrimidine derivatives as MGLUR2 antagonists F. Hoffmann-La Roche AG (CH) 2012-06-27 EP disclosed
US-8183262-B2 Central nervous system disorders; metabotropic glutamate receptors (mGluR); 2-(4-Pyridin-3-yl-imidazol-1-yl)-4-trifluoromethyl-6-(4-trifluoromethyl-phenyl)-pyrimidine HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
US-7642264-B2 Phenyl-substituted pyrimidine derivatives as mGluR antagonists HOFFMAN-LA ROCHE INC. (US) 2010-01-05 US disclosed
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GATTI MCARTHUR SILVIA 2009-12-24 US disclosed
EP-2001849-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. Hoffmann-Roche AG (CH) 2008-12-17 EP disclosed
US-7364841-B2 Comprising support having thereon light-insensitive organic silver salt grains, photosensitive silver halide grains, a reducing agent for silver ions and a binder; improved storage stability, image lasting quality; use in medical diagnosis and graphic arts KONICA MINOLTA & MEDICAL GRAPHIC, INC. (JP) 2008-04-29 US disclosed
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists HOFFMANN-LA ROCHE INC. 2007-10-04 US disclosed
WO-2007110337-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR2 ANTAGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2007-10-04 WO disclosed
US-7202019-B2 Photothermographic imaging material KONICA MINOLTA HOLDINGS, INC. (JP) 2007-04-10 US disclosed
US-7202019-B2 Photothermographic imaging material KONICA MINOLTA HOLDINGS, INC. (JP) 2007-04-10 US disclosed
US-7175978-B2 Silver salt photothermographic dry imaging material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-02-13 US disclosed
US-7175978-B2 Silver salt photothermographic dry imaging material KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-02-13 US disclosed
US-20070003886-A1 SILVER SALT PHOTOTHERMOGRAPHIC DRY IMAGING MATERIAL KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-01-04 US disclosed
US-20070003886-A1 SILVER SALT PHOTOTHERMOGRAPHIC DRY IMAGING MATERIAL KONICA MINOLTA MEDICAL & GRAPHIC, INC. (JP) 2007-01-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232583-A1 Pyridine and pyrimidine derivatives as mGIuR2 antagonists P2RX2, P2RY2, P2RX1 GSK3B 1321/4885CA2 2101/4885CA1 4351/4885
US-20090318474-A1 PYRIDINE AND PYRIMIDINE DERIVATIVES AS MGLUR 2 ANTAGONISTS GRM2, GRM1, GRM3 GSK3B 1615/4885CA2 1337/4885CA1 3811/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.